Market Closed -
Other stock markets
|
After market 11:34:34 pm | |||
520.4 EUR | +0.17% | 521 | +0.12% |
31/05 | Thermo Fisher Scientific Updates Chromosomal Microarray Analysis Solutions to Comply with IVDR Regulation | CI |
24/05 | Declaration of Voting Results by Thermo Fisher Scientific Inc | CI |
Strengths
- Before interest, taxes, depreciation and amortization, the company's margins are particularly high.
- The company returns high margins, thereby supporting business profitability.
- The average price target of analysts who are interested in the stock has been strongly revised upwards over the last four months.
- Considering the small differences between the analysts' various estimates, the group's business visibility is good.
- Analysts' price targets are all relatively close, reflecting good visibility on the company's valuation.
- The group usually releases upbeat results with huge surprise rates.
Weaknesses
- The group shows a rather high level of debt in proportion to its EBITDA.
- With an expected P/E ratio at 35.67 and 30.59 respectively for both the current and next fiscal years, the company operates with high earnings multiples.
- The company's "enterprise value to sales" ratio is among the highest in the world.
- The company appears highly valued given the size of its balance sheet.
- The company is highly valued given the cash flows generated by its activity.
- The company is not the most generous with respect to shareholders' compensation.
- For the last twelve months, sales expectations have been significantly downgraded, which means that less important sales volumes are expected for the current fiscal year over the previous period.
- For the last 12 months, analysts have been regularly downgrading their EPS expectations. Analysts predict worse results for the company against their predictions a year ago.
- The overall consensus opinion of analysts has deteriorated sharply over the past four months.
- Over the past twelve months, analysts' opinions have been revised negatively.
Ratings chart - Surperformance
Sector: Advanced Medical Equipment & Technology
1st Jan change | Capi. | Investor Rating | ESG Refinitiv | |
---|---|---|---|---|
+8.26% | 217B | - | ||
+12.28% | 190B | B- | ||
+18.86% | 143B | B- | ||
+30.03% | 111B | A- | ||
+0.65% | 64.59B | A- | ||
+14.95% | 52.36B | B+ | ||
+2.06% | 48.45B | B+ | ||
-5.37% | 38.03B | A | ||
-0.88% | 35.6B | - | ||
+19.93% | 30.31B | B+ |
Financials
Valuation
Momentum
Consensus
Business Predictability
Technical analysis
- Stock Market
- Equities
- TMO Stock
- TN8 Stock
- Ratings Thermo Fisher Scientific